Showing results (21-30 of 90) with videos related to
Sort By:
Pageof 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 7, 2014
A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cellsLina Liljenfeldt, Di Yu, Liye Chen, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 23, 2004
CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancerChristina Ninalga, Angelica Loskog, Magdalena Klevenfeldt, et al.The Prostate|January 16, 2007
Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapyBjörn Carlsson, Ole Forsberg, Mats Bengtsson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapyJustyna Leja, Helena Dzojic, Elisabet Gustafson, et al.EMBO Molecular Medicine|May 19, 2016
Safe engineering of CAR T cells for adoptive cell therapy of cancer using long-term episomal gene transferChuan Jin, Grammatiki Fotaki, Mohanraj Ramachandran, et al.Frontiers in Immunology|November 13, 2023
Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancerAlessandra Vaccaro, Tiarne van de Walle, Mohanraj Ramachandran, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunitySara M Mangsbo, Christina Ninalga, Magnus Essand, et al.Human Gene Therapy|July 30, 2013
Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapyChuan Jin, Di Yu, Matko Čančer, et al.Cancer Immunology, Immunotherapy : CII|August 25, 2007
CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patientsSofia Vikman, Valeria Giandomenico, Roberta Sommaggio, et al.Molecular Therapy. Methods & Clinical Development|May 28, 2015
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factorsChuan Jin, Di Yu, Victoria Hillerdal, et al.Pageof 9